Michael Kelly

Michael Kelly brings more than 25 years of pharmaceutical industry expertise. He recently served as president of U.S. operations for Adapt Pharma, which developed and commercialized NARCAN® (naloxone HCl) Nasal Spray, the first and only needle-free formulation of naloxone approved by the U.S. Food and Drug Administration and Health Canada. Under Mr. Kelly’s leadership, NARCAN rapidly gained market share in the U.S. from needle-based delivery of naloxone, with sales estimated to reach $200 million to $220 million in 2019, at the time of the acquisition of Adapt Pharma by Emergent Biosolutions in October 2018 for $735 million. Prior to Adapt, he served as chief executive officer and board member for Covis Pharmaceuticals, Inc. Mr. Kelly was also a member of the founding management team of Azur Pharma and later, following a strategic merger, served as senior vice president of sales and marketing for Jazz Pharmaceuticals plc. Prior to his tenure at Azur, he served as Vice President of Commercial Operations at Guilford Pharmaceuticals, Vice President of Sales and Marketing at ViroPharma Incorporated, and held various commercial and medical roles at TAP Pharmaceuticals.

Mr. Kelly holds a Bachelor of Science in business administration from The College of New Jersey and a Master of Business Administration from Rider University.